Related by context. All words. (Click for frequent words.) 72 ganetespib 72 alvespimycin 72 carfilzomib 72 PXD# 72 obatoclax 71 MGCD# [001] 71 Azedra 70 IMGN# 70 HGS ETR1 70 Perifosine 70 Carfilzomib 70 OXi# 70 T DM1 69 PEG SN# 69 JAK inhibitor 69 INCB# [002] 69 perifosine 69 deforolimus 69 ixabepilone 69 GRN#L 69 OncoVEX GM CSF 69 INCB# [001] 69 Phase Ib 69 Phase Ib study 69 phase IIb clinical 68 axitinib 68 BAY #-# 68 ponatinib 68 vascular disrupting agent 68 registrational 68 tanespimycin 68 Cloretazine ® 68 XL# [003] 68 CR# vcMMAE 68 Amrubicin 68 JAK2 inhibitor 68 IMC A# 68 anticancer compound 68 proteasome inhibitor 68 Cloretazine R VNP#M 68 Tarvacin TM 68 Sym# 67 enzastaurin 67 ATL# [001] 67 HCV protease inhibitor 67 HGS ETR2 67 Ceflatonin 67 pralatrexate 67 huC# DM4 67 Tyrima 67 tesetaxel 67 ENMD # 67 Phase Ib II 67 eniluracil 67 imetelstat 67 PLX# 67 EOquin TM 67 MEK inhibitor 67 CEQ# 67 HuMax EGFr 67 TREANDA 67 investigational humanized monoclonal antibody 67 belinostat 67 DXL# 67 BiTE antibody 67 phase IIa clinical 67 CCX# 67 Azixa 67 Tamibarotene 67 SAR# [004] 66 forodesine 66 ALN VSP 66 glufosfamide 66 OncoVEX 66 Marqibo 66 Bortezomib 66 oral prodrug 66 AEG# 66 sapacitabine 66 RGB # 66 VEGF Trap 66 brentuximab vedotin 66 ASONEP 66 HGS# 66 L BLP# 66 Atiprimod 66 Phenoptin 66 CYT# 66 elotuzumab 66 voreloxin 66 hematological cancers 66 pertuzumab 66 CA4P 66 Traficet EN 66 Pralatrexate 66 talabostat 66 PLK1 SNALP 66 tezampanel 65 MDV# 65 HuMax CD4 65 Phase #b/#a 65 angiogenesis inhibitor 65 orally bioavailable 65 EOquin 65 Nanobody 65 NGX# 65 GAP #B# 65 metaglidasen 65 Archexin 65 mertansine 65 ALN TTR 65 NVA# 65 Allovectin 7 65 protein kinase inhibitor 65 anticancer agent 65 dacetuzumab 65 PSN# [002] 65 SCH # 65 OMAPRO 65 PRT# 65 satraplatin 65 Virulizin ® 65 Tesetaxel 65 seliciclib 65 tamibarotene 65 neratinib 65 MLN# 65 UPLYSO 65 FOLOTYN 65 Tarvacin 65 Panzem R NCD 65 HCD# [002] 65 mapatumumab 65 HER2 positive metastatic breast 65 AVN# [001] 65 vosaroxin 65 ridaforolimus 65 radiation sensitizer 65 ZYBRESTAT 65 Voreloxin 65 CUDC 65 IMA# 65 CBLC# 65 phase IIb 65 PCK# 65 Bezielle 65 Aplidin 65 resistant ovarian cancer 65 PI3K/Akt pathway inhibitor 65 RDEA# 64 lorvotuzumab mertansine 64 Restanza 64 ALN PCS 64 clofarabine 64 PF # [001] 64 HspE7 64 dose escalation Phase 64 registrational trial 64 AQ4N 64 pan HDAC inhibitor 64 PSMA ADC 64 Treanda 64 refractory multiple myeloma 64 Exelixis XL# 64 phase Ib 64 HuLuc# 64 entinostat 64 anti leukemic 64 YONDELIS 64 ongoing Phase 1b 64 methylnaltrexone 64 heavily pretreated 64 ProLindac 64 hematological malignancies 64 AeroLEF TM 64 MEK inhibitors 64 tesmilifene 64 trastuzumab DM1 T DM1 64 PEG Interferon lambda 64 IL# PE#QQR 64 valopicitabine 64 talactoferrin 64 R#/MEM # 64 Romidepsin 64 Zolinza 64 blinatumomab 64 ASA# 64 BRIM3 64 IMC #B 64 RNAi therapeutic 64 Mipomersen 64 Cloretazine R 64 REOLYSIN ® 64 Cloretazine 64 Phase 2a trial 64 BRAF inhibitor 64 TACI Ig 64 CD# antibody [001] 64 XmAb# 64 thymalfasin 64 BRIM2 64 huN# DM1 64 Omacetaxine 64 OMP #M# 64 Quinamed 64 Targretin 64 PEG PAL 64 ELACYT 64 Debio 64 otelixizumab 64 docetaxel Taxotere R 64 omacetaxine 64 Amigal 64 Hsp# inhibition 64 CYC# 64 Panzem 64 HDAC Inhibitor 64 castration resistant prostate cancer 64 oral ridaforolimus 64 Seliciclib 64 Onconase 64 romidepsin 64 Phase 2b trial 64 crizotinib PF # 64 dasatinib 63 Fodosine 63 novel anticancer 63 amrubicin 63 depsipeptide 63 platinum refractory 63 ELND# 63 receptor tyrosine kinase inhibitor 63 EndoTAG TM -1 63 Advexin 63 Chemophase 63 IAP inhibitors 63 antitumor activity 63 refractory Hodgkin lymphoma 63 Exherin TM 63 Golimumab 63 relapsed multiple myeloma 63 tivozanib 63 TRO# 63 darinaparsin 63 Phase Ib clinical 63 cell lymphoma CTCL 63 LEP ETU 63 Phase #b/#a clinical 63 tipifarnib 63 Xanafide 63 brentuximab vedotin SGN 63 ThermoDox R 63 picoplatin 63 Reolysin 63 vorinostat 63 mipomersen 63 MAGE A3 ASCI 63 chemotherapeutic agent 63 elesclomol 63 Genasense ® 63 ruxolitinib 63 farletuzumab 63 Troxatyl 63 Symadex 63 KRN# 63 pomalidomide 63 Dapagliflozin 63 rALLy trial 63 Belinostat 63 Nexavar ® 63 vismodegib 63 torezolid phosphate 63 celgosivir 63 ONCONASE 63 Cotara 63 Annamycin 63 Plicera 63 Alocrest 63 Phase 1b 63 FOLOTYN ® 63 non nucleoside HCV 63 vascular disrupting agents 63 Dacogen injection 63 trastuzumab DM1 63 Gleevec resistant 63 BNC# 63 PDX pralatrexate 63 histone deacetylase HDAC inhibitor 63 Phase 2b 63 ZK EPO 63 LY# [003] 63 Reverset 63 ISIS # 63 vemurafenib 63 eculizumab 63 aflibercept 63 TG# [003] 63 Velcade bortezomib 63 dose escalation 63 tubulin inhibitor 63 Aplidin R 63 relapsed refractory multiple myeloma 63 Hsp# Inhibitor 63 ATL# [002] 63 Phase IIa clinical 63 NU# [001] 63 oral deforolimus 63 Imprime PGG 63 PRTX 63 Panzem R 63 kinase inhibitor 63 teduglutide 63 Guanilib 63 IRX 2 63 ADVEXIN 63 HuMax CD# 63 JAK1 63 Asentar 63 investigational pan BCR 63 taxane 63 Hsp# inhibitor 63 PNP inhibitor 63 INC# 63 Neuradiab 63 mitogen activated ERK kinase 63 docetaxel Taxotere ® 63 riociguat 63 selective androgen receptor modulator 63 Xcytrin 63 targeting CD# 63 solid tumors 63 Phase 1a 63 fosbretabulin 63 lumiliximab 63 Darinaparsin 63 liposomal formulation 63 lintuzumab 63 TG# [001] 62 Virulizin R 62 bicifadine 62 Telaprevir 62 Akt inhibitor 62 anticancer agents 62 subcutaneous formulation 62 IIa trial 62 PDE4 inhibitor 62 immunotherapeutic agent 62 Pazopanib 62 bendamustine 62 JAK inhibitors 62 vilazodone 62 rNAPc2 62 ARIKACE ™ 62 ZOLINZA 62 atacicept 62 Allovectin 7 R 62 TELCYTA 62 Satraplatin 62 PI3K inhibitor 62 ALN RSV# 62 bevacizumab Avastin ® 62 SUCCEED trial 62 MOZOBIL 62 palifosfamide 62 Glufosfamide 62 evaluating tivozanib 62 Genz # 62 Phase 2a clinical 62 Actemra 62 RNAi therapeutic targeting 62 dose cohorts 62 tafamidis 62 DOS# 62 APD# 62 LAF# 62 cutaneous T cell 62 antitumor 62 CoFactor 62 Alpharadin 62 HSP# inhibitor 62 RG# [001] 62 GALNS 62 rALLy 62 OvaRex ® MAb 62 Allovectin 7 ® 62 Ridaforolimus 62 CBLB# 62 elacytarabine 62 Opexa 62 humanized monoclonal antibody 62 Elesclomol 62 synthetic retinoid 62 Phase IIb clinical trials 62 novel VDA molecule 62 Blinatumomab 62 phase 2a 62 Aurora kinase inhibitor 62 #D#C# 62 Curaxin 62 Phase 2a 62 Aurora kinase 62 favorable pharmacokinetic profile 62 XL# XL# 62 SNT MC# 62 confirmatory Phase 3 62 Aurora kinase inhibitors 62 Elagolix 62 CCR5 antagonist 62 Civacir 62 Phase 2b clinical 62 tyrosine kinase inhibitor 62 Corlux 62 GRN# 62 TOCOSOL Paclitaxel 62 Sapacitabine 62 MNTX 62 HCV protease 62 ATL/TV# 62 AEGR 62 bardoxolone 62 investigational compound 62 phase IIa 62 Phase III 62 MGd 62 Trofex 62 ENMD 62 vidofludimus 62 PKC# 62 oxidative stress inducer 62 ISTODAX 62 ThermoDox ® 62 MAbs 62 nucleoside 62 bortezomib Velcade 62 BAL# [002] 62 lymphoma CTCL 62 OPAXIO 62 Proxinium TM 62 Onco TCS 62 Triolex 62 ToGA 62 oral methylnaltrexone 62 pharmacokinetic PK 62 trabectedin 62 phase IIb trial 62 nab paclitaxel 62 Onalta ™ 62 NXL# 62 eltrombopag 62 Maribavir 62 Phase #/#a trial 62 multi kinase inhibitor 62 bavituximab 62 Dasatinib 61 OHR/AVR# 61 PrevOnco 61 PEP# [003] 61 anti angiogenic therapy 61 pediatric acute lymphoblastic 61 relapsed ovarian cancer 61 dose escalation trial 61 MGCD# [002] 61 INT# [002] 61 Ceflatonin R 61 SERMs 61 APOPTONE 61 preclinically 61 Phase 2b study 61 elvucitabine 61 cetuximab Erbitux 61 Tanespimycin 61 Vitaxin 61 immunomodulator 61 small molecule Hedgehog 61 humanized antibody 61 NEUVENGE 61 PRX # 61 Pivotal Phase III 61 NP2 Enkephalin 61 polymerase inhibitor 61 xenograft models 61 Urocidin 61 antibody MAb 61 delafloxacin 61 PS# [001] 61 Squalamine 61 alkylating agent 61 velafermin 61 ARRY # 61 Laquinimod 61 orally administered inhibitor 61 chemopreventive agent 61 Fx #A 61 Genasense 61 radezolid 61 sunitinib malate 61 ALN TTR# 61 galiximab 61 HIV integrase inhibitor 61 torezolid 61 BiTE 61 LBH# 61 Insegia 61 Erlotinib 61 ozarelix 61 Taxotere ® 61 PARP inhibitor 61 BrachySil TM 61 BAL# [001] 61 olaparib 61 novel histone deacetylase 61 imatinib Gleevec ® 61 MOR# 61 PI3 kinase inhibitors 61 Phase 1b trial 61 Enzastaurin 61 BCX# 61 luliconazole 61 novel mTOR inhibitor 61 FTY# 61 MORAb 61 trastuzumab emtansine T DM1 61 Pertuzumab 61 L Annamycin 61 XL# XL# XL# 61 preclinical studies 61 RhuDex ® 61 S/GSK# 61 tolevamer 61 FGFR 61 Lenocta 61 hematologic malignancies 61 nonclinical studies 61 HRPC 61 AZX# 61 Phase IIIb clinical 61 #I TM# 61 Phase IIb trial 61 chemotherapeutic agents 61 metastatic renal cell carcinoma 61 GRNVAC1 61 placebo controlled Phase 61 BZL# 61 IAP inhibitor 61 Phase III clinical 61 GSK# [001] 61 confirmatory Phase III 61 GW# [003] 61 Bicifadine 61 Apaziquone 61 ANG# 61 multicenter Phase II 61 DAVANAT R 61 Hedgehog pathway inhibitor 61 Aflibercept 61 maribavir 61 Gemzar ® 61 teriflunomide 61 dasatinib Sprycel ® 61 gastrointestinal stromal tumors GIST 61 HQK 61 forodesine hydrochloride 61 molecularly targeted 61 metastatic CRC 61 T#I mutant 61 refractory CTCL 61 LE DT 61 oral antiviral 61 histone deacetylase inhibitor 61 rxRNA 61 LymphoStat B 61 atrasentan 61 HDAC inhibitor 61 posaconazole 61 CCR2 61 Pimavanserin 61 bortezomib Velcade R 61 erlotinib Tarceva ® 61 Protectan CBLB# 61 Elvitegravir 61 volociximab 61 KNS # 61 ACZ# 61 CIMZIA ™ 61 pitavastatin 61 abiraterone 61 ularitide 61 Amplimexon 61 biologic therapy 61 OvaRex R 61 Phase 1a clinical 61 metastatic melanoma 61 Trastuzumab DM1 61 TMC# [002] 61 virus HCV protease inhibitor 61 bortezomib 60 Irinotecan 60 BLA filing 60 PANVAC VF 60 Ambrisentan 60 cilengitide 60 bortezomib Velcade ® 60 ospemifene 60 anticancer therapy 60 metastatic hormone refractory 60 ISF# 60 telomerase therapeutic 60 oral taxane 60 epothilone 60 PEGylated 60 refractory CLL 60 Phase 1b clinical 60 AKT inhibitor 60 Phase IIB 60 placebo controlled clinical 60 milatuzumab 60 Telavancin 60 dexpramipexole 60 evaluating satraplatin 60 anti TNF alpha 60 iclaprim 60 Phase IIa trials 60 EGS# 60 Protexia R 60 trodusquemine 60 B CLL 60 DermaVir Patch 60 humanized anti 60 chronic lymphocytic leukemia CLL 60 GLP toxicology studies 60 indolent NHL 60 TRV# [001] 60 antibody MT# 60 Zensana TM 60 ISENTRESS 60 leukemia AML 60 PEGPH# 60 LHRH antagonist 60 NEUMUNE 60 pharmacokinetic PK study 60 oral Azacitidine 60 refractory chronic lymphocytic 60 panobinostat 60 ofatumumab 60 gefitinib Iressa 60 AMN# [001] 60 DAVANAT 60 brostallicin 60 HDACi 60 sorafenib Nexavar 60 Bafetinib 60 triphendiol 60 DU #b 60 seliciclib CYC# 60 Cetrorelix 60 histologies 60 lupus nephritis 60 TELINTRA 60 Kahalalide F 60 alvimopan 60 PHX# 60 TRIOLEX 60 panitumumab 60 heavily pretreated patients 60 cytostatic 60 CD# monoclonal antibody 60 kinase inhibitors 60 OMP #R# 60 darapladib 60 mRCC 60 ZEVALIN 60 nimotuzumab 60 LUX Lung 60 Onrigin 60 TLK# 60 Exelixis compounds 60 PREOS R 60 preclinical 60 XL# XL# XL# XL# 60 adecatumumab MT# 60 pivotal Phase III 60 Huntexil 60 SCCHN 60 ADXS# 60 Zybrestat 60 perifosine KRX 60 refractory acute myeloid 60 ZYBRESTAT TM 60 ON #.Na 60 polymerase inhibitors 60 custirsen 60 Menerba 60 taxanes 60 bevacizumab Avastin 60 CIMZIA TM 60 phase Ib clinical 60 CCX# B 60 #ME# 60 superficial bladder cancer 60 zanolimumab 60 dose cohort 60 peginesatide 60 epothilones 60 AzaSite Plus 60 cediranib 60 ARIKACE 60 chronic myeloid leukemia CML 60 LUMINATE 60 apaziquone 60 adecatumumab 60 Pathway Inhibitor 60 CORT # 60 glucokinase activator 60 nilotinib 60 AVE# 60 ascending dose 60 Provecta 60 Vandetanib 60 erlotinib Tarceva 60 IDX# 60 dalbavancin 60 XYOTAX TM 60 metastatic HRPC 60 CYT# potent vascular disrupting 60 rindopepimut 60 TriRima 60 GLPG# 60 daclizumab 60 VEGF receptor inhibitor 60 GV# [001] 60 velafermin belinostat 60 Naproxcinod 60 Icatibant 60 Sphingomab 60 cabozantinib 60 Neulasta ® 60 GLYX 60 EGFR inhibitors 60 isoform selective 60 gefitinib 60 dose escalation clinical 60 Ocrelizumab 60 sodium glucose cotransporter 60 HER2 antibody 60 MAXY G# 60 cMET 60 viral kinetics 60 relapsed MM 60 MAP# 60 omacetaxine mepesuccinate 60 Factor VIIa 60 Zerenex 60 preclinical efficacy 60 Hedgehog Pathway Inhibitor 60 generation Hsp# inhibitor 60 XYOTAX 60 Phase #/#a 60 RAV# 60 Randomized Phase 60 hA# 60 cannabinor 60 SUTENT ® 60 vandetanib 60 Panzem NCD 60 Kevetrin ™ 60 Stimuvax R 60 antitumour activity 60 GMX# 60 SinuNase 60 antiangiogenic activity 60 metastatic sarcomas 60 assessing T DM1 60 anticancer therapies 60 Folotyn 60 PROSTVAC TM 60 iSONEP 60 metastatic RCC 60 EGFR HER2 60 Evoltra ® 60 Plenaxis TM 60 TroVax 60 regorafenib 60 HGS ETR1 mapatumumab 60 PTK ZK 60 Neuvenge 60 Nimotuzumab 60 GAMMAGARD 60 nucleoside analogue 60 BIBW 60 LymphoStat B TM 60 ABL inhibitor 60 Aurexis 60 relapsed MCL 60 VELCADE 60 Rexin G 60 evaluating Xcytrin 60 TAFA# 60 NSCLC 59 Vidofludimus 59 targeted radiotherapeutic 59 demonstrated antitumor activity 59 refractory AML 59 proteasome inhibitors 59 Ixempra 59 Azedra TM 59 solithromycin 59 generation purine nucleoside 59 Marqibo TM 59 Herceptin trastuzumab 59 Valortim R 59 Erbitux cetuximab 59 ocrelizumab 59 indibulin 59 ganaxolone 59 investigational monoclonal antibody 59 Deforolimus 59 BENLYSTA 59 cancer immunotherapies 59 rhC1INH 59 reslizumab 59 corticosteroid dexamethasone 59 T#I [002] 59 Talabostat 59 refractory APL 59 PROCHYMAL 59 Dalbavancin 59 mTOR inhibitors 59 ProLindac TM 59 Alzhemed TM 59 CLORETAZINE TM VNP#M 59 ambrisentan 59 diabetic nephropathy 59 eprotirome 59 chemotherapeutic drug 59 Anticalin R 59 immunomodulatory 59 relapsed refractory 59 VEGF inhibitors 59 SIMPONI 59 leukemia CLL 59 bafetinib 59 ALKS 59 CRLX# 59 JAK3 59 investigational hepatitis C 59 Cethromycin 59 relapsing remitting multiple sclerosis 59 refractory gout 59 Solazed TM 59 Epothilones 59 Initiate Phase 59 MEK inhibitor RDEA# 59 imatinib resistant 59 retapamulin 59 registrational trials 59 Tavocept 59 MAb 59 TBC# 59 nucleoside reverse transcriptase inhibitor 59 incyclinide 59 Avastin bevacizumab 59 gemcitabine 59 initiate Phase 1b 59 ceftaroline 59 Phase IIb trials 59 MEND CABG II 59 Solazed 59 MyVax R 59 disease modifying 59 randomized controlled Phase 59 systemically administered 59 non nucleoside inhibitor 59 ALK inhibitor 59 TLR9 agonists 59 eosinophilic asthma 59 Prodarsan ® 59 orBec 59 epratuzumab 59 pharmacodynamic PD 59 UVIDEM 59 ApoB SNALP 59 paclitaxel Taxol ® 59 PD LID 59 BCR ABL inhibitors 59 ARRY 59 apoptosis inducer 59 motesanib 59 alpha antagonist 59 Vilazodone 59 Ixabepilone 59 Curaxin CBLC# 59 AAG geldanamycin analog 59 PREOS 59 pralatrexate injection 59 Maraviroc 59 IND submission 59 BrachySil 59 Cutaneous T 59 dirucotide 59 CRx 59 dexanabinol 59 dasatinib Sprycel 59 rBChE 59 VEGF receptor 59 Nasulin 59 PNT# 59 thalidomide Thalomid 59 Nanobodies 59 randomized Phase III 59 Ofatumumab 59 telomerase inhibitor drug 59 mGluR5 NAM 59 QVA# 59 diabetic neuropathic pain 59 ANAVEX #-# [003] 59 Zalbin 59 Epratuzumab 59 CD3 monoclonal antibody 59 IgG1 monoclonal antibody 59 ipilimumab 59 HCV polymerase 59 RLY# 59 Phase III TRIST 59 Revlimid lenalidomide 59 limiting toxicity 59 dextromethorphan quinidine 59 Fludara 59 BN# [002] 59 recurrent glioblastoma multiforme 59 brivaracetam 59 signal transduction inhibitor 59 targeted antifolate 59 GVAX 59 durable remissions 59 afatinib 59 clevudine 59 bone metastasis 59 AMD# [003] 59 ENDEAVOR IV 59 Pixantrone 59 Darusentan 59 Tarceva TM 59 Spiegelmer ® 59 leading oral taxane 59 elagolix 59 M Vax 59 AEOL # 59 CDP# 59 OMNARIS HFA 59 lomitapide 59 SUTENT 59 Taxotere R 59 Pirfenidone 59 nucleoside analog 59 recurrent GBM 59 pegylated interferons 59 myeloproliferative disorders 59 rituximab Rituxan 59 oncolytic vaccine 59 Stedivaze 59 BCIRG 59 Atu# 59 novel peptide 59 ZEVALIN ® 59 dosing cohort 59 Prostate AdenoCarcinoma Treatment 59 zalutumumab 59 oral JAK1 59 ThermoDox 59 Glybera 59 Hepatocellular Carcinoma HCC 59 Phase IIa trial 59 GATTEX ® 59 mGluR5 negative 59 therapeutic monoclonal antibodies 59 Vicinium TM 59 Antisense 59 Omnitarg 59 Cimzia ® certolizumab pegol 59 Daclizumab 59 Orazol 59 SIRT1 activators 59 Diamyd ® 59 Virulizin 59 Gleevec imatinib mesylate 59 Nanobody ® 59 cancer immunotherapy 59 drug conjugate 59 HIF PHI 59 temsirolimus 59 octreotide implant 59 alpha folate receptor 59 oral picoplatin 59 Anthim 59 multiple myeloma MM 59 Valortim ® 59 DPP4 59 Li Fraumeni Syndrome 59 hormone refractory prostate cancer